Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years

被引:31
|
作者
McClung, M. R. [1 ]
Balske, A. [2 ]
Burgio, D. E. [3 ]
Wenderoth, D. [4 ]
Recker, R. R. [5 ]
机构
[1] Oregon Osteoporosis Ctr, Portland, OR 97213 USA
[2] Abbott Labs, Abbott Pk, IL 60064 USA
[3] Procter & Gamble Co, Mason, OH USA
[4] Warner Chilcott Deutschland GmbH, Weiterstadt, Germany
[5] Creighton Univ, Osteoporosis Res Ctr, Omaha, NE 68178 USA
关键词
Bone mineral density; Delayed-release; Enteric-coated; Histomorphometry; Osteoporosis; Risedronate; Weekly; LONG-TERM RISEDRONATE; NONVERTEBRAL FRACTURES; BISPHOSPHONATE THERAPY; VERTEBRAL FRACTURES; BONE QUALITY; WOMEN; ALENDRONATE; EFFICACY; ARCHITECTURE; RISK;
D O I
10.1007/s00198-012-2175-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bone mineral density response to once weekly delayed-release formulation of risedronate, given before or following breakfast, was non-inferior to that seen with traditional immediate-release risedronate given daily before breakfast. Delayed-release risedronate is a convenient dosing regimen for oral bisphosphonate therapy that might avoid poor compliance. This 2-year, randomized, controlled, non-inferiority study assessed the efficacy and safety of a delayed-release (DR) 35-mg weekly oral formulation of risedronate that allows subjects to take their weekly risedronate dose before or immediately after breakfast. Results from the first year of the study were published previously (McClung et al. Osteoporos Int 23(1):267-276, 2012); we now report the final results after 2 years. Women with postmenopausal osteoporosis were randomly assigned to receive risedronate 5 mg immediate-release (IR) daily (n = 307) at least 30 min before breakfast, or risedronate 35 mg DR weekly, either immediately following breakfast (FB, n = 307) or at least 30 min before breakfast (BB, n = 308). Bone mineral density (BMD), bone turnover markers (BTMs), fractures, adverse events, and bone histomorphometry were evaluated. A total of 248 subjects (80.8 %) in the IR daily group, 234 subjects (76.2 %) in the DR FB weekly group, and 240 subjects (77.9 %) in the DR BB weekly group completed the 2-year study. After 2 years of treatment, BMD increases at the lumbar spine and total hip with the weekly DR doses similar to or greater than that with the IR daily dose. Decreases in BTMs were similar or significantly lower in the DR groups. Bone histomorphometry results did not differ among the DR weekly and the IR daily formulations. The three regimens were similarly well tolerated. Risedronate 35 mg DR weekly is as effective and as well tolerated as risedronate 5 mg IR daily, and will allow subjects to take their weekly risedronate dose immediately after breakfast.
引用
收藏
页码:301 / 310
页数:10
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS OF ACTONEL® 35 MG (RISEDRONATE) GASTRO-RESISTANT TABLETS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS IN FRANCE
    Hiligsmann, M.
    Reginster, J.
    VALUE IN HEALTH, 2018, 21 : S298 - S298
  • [32] TREATMENT WITH ONCE-WEEKLY ALENDRONATE 70 MG COMPARED TO ONCE-WEEKLY RISEDRONATE 35 MG IN WOMEN WITH POSTMENOPAUSALE OSTEOPOROSIS: A RANDOMIZED DOUBLE-BLIND STUDY
    Pietschmann, Peter
    JOURNAL FUR MINERALSTOFFWECHSEL, 2005, 12 (01): : 36 - 38
  • [33] Evaluation of weekly risedronate treatment in postmenopausal women with osteoprotegerin
    Karadag-Saygi, E.
    Bizargity, P.
    Ay, P.
    Saygi, B.
    Akyuz, G.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S339 - S340
  • [34] Evaluation of weekly risedronate treatment in postmenopausal women with osteoprotegerin
    Gulseren, A.
    Peyman, B.
    Pinar, A.
    PANMINERVA MEDICA, 2011, 53 (02) : 75 - 80
  • [35] FIVE YEARS OF TREATMENT WITH RISEDRONATE AND ITS EFFECTS ON BONE SAFETY IN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS
    Sod, E.
    Johnson, T. D.
    Chines, A.
    Melsen, F.
    CALCIFIED TISSUE INTERNATIONAL, 2004, 74 : S80 - S80
  • [36] Five Years of Treatment with Risedronate and its Effects on Bone Safety in Women with Postmenopausal Osteoporosis
    L.-G. Ste-Marie
    E. Sod
    T. Johnson
    A. Chines
    Calcified Tissue International, 2004, 75 : 469 - 476
  • [37] Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis
    Ste-Marie, LG
    Sod, E
    Johnson, T
    Chines, A
    CALCIFIED TISSUE INTERNATIONAL, 2004, 75 (06) : 469 - 476
  • [38] Efficacy and Safety of Risedronate Sodium in Treatment of Postmenopausal Osteoporosis
    李裕明
    张众志
    邓秀玲
    陈璐璐
    华中科技大学学报(医学英德文版), 2005, (05) : 527 - 529
  • [39] Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis
    Cranney, A
    Tugwell, P
    Adachi, J
    Weaver, B
    Zytaruk, N
    Papaioannou, A
    Robinson, V
    Shea, B
    Wells, G
    Guyatt, G
    ENDOCRINE REVIEWS, 2002, 23 (04) : 517 - 523
  • [40] Efficacy and safety of risedronate sodium in treatment of postmenopausal osteoporosis
    Li Yuming
    Zhang Zhongzhi
    Deng Xiuling
    Chen Lulu
    Journal of Huazhong University of Science and Technology [Medical Sciences], 2005, 25 (5): : 527 - 529